Boehringer Ingelheim’s Cyltezo Pen Receives the US FDA’s Approval for Cyltezo, an Interchangeable Biosimilar to Humira
Shots:
- The US FDA has approved Cyltezo Pen, an autoinjector option of Cyltezo (the US FDA-approved Interchangeable biosimilar to Humira)
- Additionally, 40mg/0.8mL pre-filled Cyltezo Pen will be available in two, four, and six-pack options on July 1, 2023. Cyltezo was initially approved as a pre-filled syringe, indicated to treat multiple chronic inflammatory diseases incl. RA, JIA, CD, and PsO
- Additionally, Cyltezo Pen features a one-button, 3-step activation with 100% drug visibility and a protected needle. In 2021, Cyltezo became the first approved interchangeable biosimilar to treat certain inflammatory diseases
Ref: Boehringer Ingelheim | Image: Boehringer Ingelheim
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
